Volibo R 0.2/0.5 mg
| SKU | 2605 |
|---|---|
| Generic For | Voglibose R |
| Manufacturer | Ajanta Pharma India |
| Active Ingredient | Voglibose / Repaglinide |
| Pack Size | Qty | Price Per Pill or Unit | Price | Cart | |
|---|---|---|---|---|---|
| 30 Tablet/s | US$ 0.69 | US$ 20.70 | |||
|
|||||
| 60 Tablet/s | US$ 0.62 | US$ 37.2610%US$ 41.40 | |||
|
|||||
| 90 Tablet/s | US$ 0.59 | US$ 52.7815%US$ 62.10 | |||
|
|||||
Volibo R 0.2/0.5mg – Affordable Voglibose R Alternative
Volibo R 0.2/0.5mg is a combination of Repaglinide and Voglibose, which belongs to the group of medicines called antidiabetic agents. It is primarily used for the treatment of Type 2 diabetes. Type 2 diabetes is a health condition in which your cells do not normally respond to insulin, a hormone that regulates how your body utilizes sugar. This leads to increased blood sugar, leading to serious health complications.
Repaglinide works by increasing the amount of insulin released by the pancreas. At the same time, Voglibose causes the breakdown of complex sugars into simple sugar such as glucose. Together, they prevent the elevation of blood sugar after meals. You may be advised to take Volibo R with a healthy diet, exercise, and other antidiabetic agents to control blood sugar.
Precautions Volibo R 0.2/0.5 mg
Volibo R is not recommended for use in patients allergic to repaglinide and Voglibose. It can cause low blood sugar levels with other antidiabetic agents, alcohol, or if you delay a meal. The fixed-dose antidiabetic medicine is not recommended in patients with type 1 diabetes or diabetic ketoacidosis (one of the most serious complications of diabetes mellitus), severe infection, gastrointestinal obstruction, and moderate to severe liver disease. Before taking Voglibose/repaglinide, let your doctor know if you are scheduled for major surgery or have a severe illness, trauma, fever, chronic intestinal disease, and kidney problems.
Side effects of Volibo R 0.2/0.5 mg
This combination medication's most common side effects include diarrhoea, flatulence, stomach pain, hypoglycemia (low blood sugar), and skin rash. However, these are temporary and usually resolve on their own. Please consult your doctor if these do not resolve or persist for longer. Monitor your blood sugar levels regularly while taking this medicine.
How to use Volibo R 0.2/0.5 mg
You may be advised to take Volibo R 0.2/0.5 mg around fifteen minutes before a main meal. While receiving this antidiabetic agent, making certain lifestyle modifications, such as consuming a healthy and balanced diet, staying active, quitting smoking, and regularly monitoring your blood sugar level, is essential. This helps to manage your condition and improves your health. Always carry some sugary food to manage symptoms of low blood sugar levels, including pale skin, cold sweats, anxiety, and tremors.
Check with your doctor before using this medicine if the following conditions apply to you:
- Pregnancy or women planning for pregnancy.
- Breastfeeding women.
- The antidiabetic agent should not be given to children and adolescents (under 18 years) and to the elderly (aged above 75 years).
What is Volibo R 0.2/0.5mg and what condition does it treat?
Volibo R 0.2/0.5mg is a combination diabetes medication containing two active ingredients: voglibose (0.2mg) and repaglinide (0.5mg). This antidiabetic tablet is prescribed for managing type 2 diabetes mellitus in adults when blood sugar control cannot be achieved through diet, exercise, or single-agent therapy alone. Voglibose belongs to the alpha-glucosidase inhibitor class, while repaglinide is a meglitinide antidiabetic agent. Together, these components work through complementary mechanisms to help regulate blood glucose levels throughout the day, particularly controlling post-meal sugar spikes and fasting glucose levels in diabetic patients.
How does the combination of Voglibose and Repaglinide work in the body?
Volibo R 0.2/0.5mg employs a dual-action mechanism for blood sugar management. Repaglinide stimulates insulin secretion from pancreatic beta cells rapidly after meals, addressing post-meal glucose spikes effectively. Meanwhile, voglibose works in the intestines by inhibiting alpha-glucosidase enzymes, which slows down carbohydrate breakdown and glucose absorption from food. This combination approach targets both insulin production and glucose absorption simultaneously, providing comprehensive glycemic control. The synergistic effect of these two antidiabetic agents helps maintain steadier blood sugar levels throughout the day compared to single-agent therapies, making this diabetes medicine particularly effective for patients requiring multi-mechanism glucose regulation.
How long does Volibo R 0.2/0.5mg take to work after taking it?
Volibo R 0.2/0.5mg begins working relatively quickly due to its repaglinide component, which starts stimulating insulin release within 15 to 30 minutes after ingestion. Peak blood levels occur approximately one hour after administration, making it effective for controlling post-meal blood sugar spikes. The voglibose component works simultaneously in the digestive tract to slow glucose absorption during the meal. While you'll experience immediate glucose-lowering effects after each dose, the full therapeutic benefit for overall diabetes management typically becomes evident after several days to weeks of consistent use as your body adjusts and blood sugar patterns stabilize with this combination antidiabetic medication.
When and how should I take Volibo R 0.2/0.5mg tablets correctly?
Volibo R 0.2/0.5mg should be taken orally immediately before meals, typically three times daily before breakfast, lunch, and dinner. Swallow the tablet whole with water within 15 minutes of starting your meal to ensure optimal glucose control. If you skip a meal, you should also skip that dose of this diabetes medicine to avoid hypoglycemia risk. Never double up on doses if you miss one. The timing is crucial because repaglinide needs food present to work safely, and voglibose must be in your system when carbohydrates arrive. Your doctor will determine the appropriate dosing schedule based on your meal patterns, blood sugar monitoring results, and overall diabetes management plan.
Is Volibo R 0.2/0.5mg safe for long-term diabetes management?
Volibo R 0.2/0.5mg can be used safely for long-term type 2 diabetes management when taken as prescribed and monitored appropriately. Many patients maintain this combination antidiabetic therapy for extended periods with good tolerability. However, long-term use requires regular medical supervision including periodic blood glucose monitoring, HbA1c testing, liver function assessments, and kidney function evaluation. Your healthcare provider will adjust dosages as needed based on your response and any changes in your diabetes condition. Regular follow-ups ensure the medication continues working effectively while minimizing risks. Long-term success with this diabetes medicine depends on maintaining healthy lifestyle habits alongside medication compliance.
Can I take Volibo R 0.2/0.5mg with other diabetes or regular medicines?
Volibo R 0.2/0.5mg may interact with various medications, so informing your healthcare provider about all drugs you take is essential. Certain medicines like gemfibrozil, trimethoprim, beta-blockers, and some antibiotics can enhance the blood sugar-lowering effect, increasing hypoglycemia risk. Conversely, corticosteroids, thiazide diuretics, and thyroid medications may reduce effectiveness. Other antidiabetic medications require careful dose adjustment when combined with this combination therapy. Alcohol consumption can also affect blood glucose unpredictably. Some herbal supplements may interfere with voglibose or repaglinide metabolism. Your doctor or pharmacist can review your complete medication list to identify potential interactions and adjust your diabetes treatment regimen safely for optimal glycemic control.
How does Volibo R 0.2/0.5mg compare to other combination diabetes medications?
Volibo R 0.2/0.5mg offers a unique combination compared to other diabetes medications. Unlike metformin-based combinations, this voglibose-repaglinide pairing provides meal-time glucose control without the gastrointestinal side effects common with biguanides. Compared to sulfonylurea combinations, repaglinide offers more flexible dosing tied to meals with shorter action duration, reducing hypoglycemia risk between meals. The alpha-glucosidase inhibitor component provides additional post-meal glucose management that DPP-4 inhibitor combinations don't specifically target. This antidiabetic combination is particularly beneficial for patients with irregular meal schedules or those who haven't achieved adequate control with single-agent therapies. Individual response varies, so your healthcare provider will determine which diabetes medicine best suits your specific metabolic profile and lifestyle.
Is generic Voglibose Repaglinide as effective as branded Volibo R?
Generic voglibose-repaglinide combinations contain identical active ingredients in the same strengths as branded Volibo R 0.2/0.5mg and are pharmaceutically equivalent. Regulatory authorities require generic diabetes medications to demonstrate bioequivalence, meaning they work in your body the same way as branded versions. The therapeutic effect, safety profile, and glucose-lowering capability remain consistent whether you use generic or branded formulations. Many patients successfully manage their type 2 diabetes with generic versions at lower costs without sacrificing effectiveness. Quality-assured generic antidiabetic medications from reputable manufacturers provide reliable blood sugar control. The choice between generic and branded options often comes down to availability, cost considerations, and personal preference rather than effectiveness differences.
Why do patients choose PremiumRxDrugs for their Volibo R 0.2/0.5mg prescription?
Patients prefer PremiumRxDrugs for Volibo R 0.2/0.5mg because of several key advantages. As a licensed international pharmacy, we guarantee authentic voglibose-repaglinide medications sourced directly from approved manufacturers, ensuring quality and effectiveness. Our competitive pricing helps patients manage ongoing diabetes treatment costs without compromising medication quality. The pharmacy's easy prescription management system simplifies refills for long-term antidiabetic therapy. Discreet, secure packaging respects patient privacy, while flexible worldwide shipping options, including free delivery, make access convenient regardless of location. With more than ten years serving diabetes patients across the USA, UK, Australia, Canada, and beyond, PremiumRxDrugs has built lasting trust through reliable service, authentic medicines, and customer-focused support for chronic condition management.
What are the common side effects of Voglibose and Repaglinide?
Common side effects of voglibose include gastrointestinal symptoms such as flatulence, abdominal bloating, diarrhea, and stomach discomfort, particularly when starting treatment. These digestive effects typically diminish as your body adjusts to the alpha-glucosidase inhibitor. Repaglinide may cause hypoglycemia (low blood sugar), especially if meals are delayed or skipped, with symptoms including dizziness, sweating, trembling, and hunger. Weight gain can occur with repaglinide due to its insulin-stimulating effect. Some patients experience headache, joint pain, or upper respiratory symptoms. Mild liver enzyme elevations occasionally appear but usually resolve. Most side effects are manageable and decrease over time. Severe reactions are uncommon but require immediate medical attention if experienced.
Who should avoid taking Voglibose and Repaglinide combination therapy?
Voglibose and repaglinide are contraindicated in several situations. Individuals with type 1 diabetes or diabetic ketoacidosis should not use this combination as it's designed specifically for type 2 diabetes management. Those with severe liver disease cannot safely metabolize repaglinide. Patients with inflammatory bowel disease, intestinal obstruction, or severe digestive disorders should avoid voglibose due to gastrointestinal effects. Pregnant or breastfeeding women require alternative diabetes treatments. People with known hypersensitivity to either active ingredient must avoid this medication. Those taking gemfibrozil should not use repaglinide due to serious interaction risks. Patients with severe kidney impairment need careful evaluation before starting this antidiabetic combination. Children typically aren't prescribed this medication as safety hasn't been established in pediatric populations.
Login
Sign Up
Login
Sign Up